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Abstract 
Background: Evidence from randomized controlled trials (RCTs) has shown a significant survival advantage of 
trastuzumab. Although extant work in developed countries examined economic evaluation of trastuzumab in 
adjuvant treatment for early breast cancer based on the 1-year treatment, there is uncertainty about 
cost-effectiveness of trastuzumab in the Adjuvant Treatment of early breast cancer in developing countries. This 
study aimed to estimate cost-effectiveness of adjuvant trastuzumab therapy compared to AC-T regimen in early 
breast cancer in Iran. 
Methods: A cost-effectiveness analysis was performed using a Markov model to estimate outcomes and costs 
over a 20-year time period using a cohort of women with HER2 positive early breast cancer, treated with or 
without 12 months trastuzumab adjuvant chemotherapy. Transition probabilities were derived mainly from the 
BCIRG006 trial. Costs were estimated from the perspective of the Iranian health care system. Both costs and 
outcomes were discounted by 3%. One-way sensitivity analysis was undertaken to assess the associated 
uncertainties in the expected output measures. 
Results: On the basis of BCIRG006 trial, our model showed that adjuvant trastuzumab treatment in early breast 
cancer, yield 0.87 quality-adjusted life-years (QALY) compared with AC-T regimen. Adjuvant trastuzumab 
treatment yielded an incremental cost-effectiveness ratio (ICER) of US$ 51302 per QALY.  
Conclusion: By using threshold of 3 times GDP per capita, as per World Health Organization (WHO) 
recommendation, 12 months trastuzumab adjuvant chemotherapy is not a cost-effective therapy for patients with 
HER2-positive breast cancer in Iran. 
Keywords: adjuant therapy, cost-effectiveness, early breast cancer, trastuzumab 
1. Introduction 
Breast cancer (BC) is the most prevalent cancer among Iranian women (Sadjadi, 2005). There were 7582 newly 
diagnosed cases in 2008 (Etemad, 2008-9) and a recent study by Mousavi (2009) reported an age standardized 
incidence rate of 28.25 per 100,000 females in 2006. Human epidermal growth factor receptor-2 is 
overexpressed in 25 to 30 percent of patients with primary breast cancer and it causes cancer cells to reproduce 
uncontrollably (D. J. Slamon et al., 1989; 2001). 
Trastuzumab (Herceptin®) is a synthetic and recombinant humanized monoclonal antibody directed against the 
extracellular domain of the (HER2). The HER2 proteins stimulate cell proliferation and trastuzumab inhibits cell 
proliferation in HER2-dependent tumors (Hudis, 2007; Leyland-Jones, 2002; D. Slamon et al., 2011). 
Trastuzumab was approved in 1998 as a first-line treatment for HER2-positive metastatic breast cancer (Kurian 
et al., 2007). Then, the indication was extended to adjuvant treatment in early breast cancer. 
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Several randomized controlled trials (RCTs) have shown a significant survival advantage of trastuzumab, with a 
reduction in the rate of recurrence and improvement in the rate of survival for early breast cancer, when added to 
conventional chemotherapy, for 1-year(Gianni et al., 2011; Piccart-Gebhart et al., 2005; Romond et al., 2005; D. 
Slamon et al., 2011). As for other monoclonal antibodies, trastuzumab has a high treatment cost compared with 
other chemotherapeutic agents; a full course of treatment with trastuzumab is about US$70,000 (Fleck, 2006). 
The average wholesale price of trastuzumab is clearly above the average price of other breast cancer drugs. 
Therefore, better health outcomes should justify the higher treatment costs. The trade-off between the costs and 
benefits is a key criteria for reimbursement (Neyt, Huybrechts, Hulstaert, Vrijens, & Ramaekers, 2008). To date, 
there is controversy in some countries about public health funding of this drug due to its high cost and limited 
overall survival benefit (Fenton, 2010).  
In developed countries, several studies conducted to determine economic evaluation of trastuzumab in adjuvant 
treatment for early breast cancer based on a 1-year treatment (Dedes et al., 2007; Garrison et al., 2007; Kurian et 
al., 2007; Millar & Millward, 2007; Liberato, Marchetti, & Barosi, 2007; Neyt et al., 2008; Hall et al., 2011; 
Skedgel, Rayson, & Younis, 2009). There is, however, uncertainty about Trastuzumab cost-effectiveness in early 
breast cancer for decision makers, in many developing countries (Buendía, Vallejos, & Pichón-Rivière, 2013). To 
the best of our knowledge, there is no study that investigated cost-effectiveness of trastuzumab treatment in Iran. 
To fill the gap in the literature, the current study aimed to estimate cost effectiveness of adjuvant trastuzumab 
therapy in early breast cancer in Iran. The findings of this study will provide useful evidence regarding efficiency 
of trastuzumab treatment for health care decision makers in the country. 
2. Patient and Method 
2.1 Model 
We implemented a Markov model based on breast cancer disease states. A Markov model with four health states 
was designed to estimate outcomes and costs for a hypothetical cohort of women with positive early breast 
cancer. 
 
 
Figure 1. Markov model structure 
 
As shown in Figure 1, the model included four health states: disease free state (DFS), loco-regional recurrence 
(local, regional and contralateral relapse), metastases recurrence and death. Based on the Markov model patients 
received their assigned adjuant therapy and remained in a state of disease-free state until they either died with 
background mortality or they experienced a loco-regional or metastatic relapse. Patients who survive with local 
recurrence can move to DFS or metastases state. Patients remain in a metastases state until they die from breast 
cancer or die from other causes. Based on BCIRG 006, congestive heart failure (CHF) was the main side-effect 
of both treatment taken into account. 
We constructed a decision tree in TreeAge Pro 2011®, (TreeAge Software, Inc) to estimate the costs and utility 
Treatment Back ground mortality 
Local or regional 
recurrence 
Disease free 
survival 
Metastases 
recurrence 
Patient with 
HER/2 positive Dead 
Death from breast cancer disease
www.ccsenet.org/gjhs Global Journal of Health Science Vol. 7, No. 1; 2015 
100 
 
effects for a hypothetical cohort of women with HER2 positive early breast cancer in two treatment strategies. 
According to BCIRG 006 trial, two treatment strategies were selected: adjuvant chemotherapy plus trastuzumab 
and adjuant chemotherapy alone. This model applied for comparing 20 years costs and effectiveness of adjuvant 
chemotherapy plus trastuzumab and adjuant chemotherapy alone for patients with HER2-positive early breast 
cancer. The average age of the population in the model was 50 years old, similar to the BCIRG 006 trials. In the 
first strategy, randomly assigned women with HER2-positive early-stage breast cancer received 100 mg/m2 
docetaxel, 60 mg/m2 doxorubicin, 600mg/m2 cyclophosphamide intravenously (AC-T arm) in each session, six 
times every 3 weeks that prolonged approximately 4 months. In second strategy, the same regimen plus 52 weeks 
of trastuzumab (AC-T plus H) is considered. We simulated a hypothetical cohort of women with an average age 
of 50 year with the same entry criteria as in the BCIRG 006 trial. The incidence of adverse effects associated 
with the adjuvant therapy was also taken into account. 
Analyses were projected to 20-year horizons. The cycle length was one year. The outcome was measured as 
life-year gained (LYG) and quality-adjusted life-year (QALY). Costs and QALYs were both discounted by 3%. 
2.2 Key Assumptions 
The following assumptions were made in the analysis: 
 Recurrence of contralateral breast cancer was combined with local and regional recurrence. 
 There were no breast cancer recurrences beyond year 20 of the model (Rivkin SE, 2003). 
 The benefit of trastuzumab treatment last for 5 years (D. Slamon et al., 2011).  
 Patients in the Adjuvant trastuzumab arm experience cardiotoxicity within the first year of treatment (D. 
Slamon et al., 2011). 
 Death due to breast cancer occurs only in metastasis disease state (Millar & Millward, 2007)  
 The cost of trastuzumab therapy in metastases state was omitted because less than 5% of patients in Iran use 
trastuzumab (Davari et al., 2013) . 
 Patients in local recurrence could transition to ‘distant recurrence’ while patients in the distant recurrence 
state remained in that state until death (D. Slamon et al., 2011). 
 In BCIRG 006 study, CHF related deaths were not reported, thus mortality due to CHF was assumed to be 
zero (D. Slamon et al., 2011). 
2.3 Clinical Data 
The underlying clinical data and the treatment protocol, follows the BCIRG 006 trial (D. Slamon et al., 2011). 
Survival probabilities for disease free state in two strategies were based on a 5-year fallow-up of the BCIRG 006 
trial (D. Slamon et al., 2011). Annual rate of recurrence after year 15 was obtain from Early Breast Cancer 
Trialists' Collaborative Group (EBCTCG, 2005). Table 1 presents more information on the clinical inputs. 
 
Table 1. Probability parameters 
Parameters Base-case estimate Reference 
Cumulative probability for DFS in AC-T group, year 5 0.75 (D. Slamon et al., 2011) 
Hazard ratio for DFS in AC-TH group, year 5 0.64 (D. Slamon et al., 2011) 
Hazard ratio for DFS in AC-TH group, year 6-20 1 Assumed 
Annual rate of recurrence, years 5-9 4.89% (EBCTCG, 2005) 
Annual rate of recurrence, year 10-14 3.54% (EBCTCG, 2005) 
Annual rate of recurrence after year 15 2.66% (EBCTCG, 2005) 
Proportion of loco-regional versus metastases disease 0.25 (Piccart-Gebhart et al., 2005) 
Incidence of congestive heart failure in AC-T group 0.7% (D. Slamon et al., 2011) 
Incidence of congestive heart failure in AC-TH group 2% (D. Slamon et al., 2011) 
Annual rate of death from metastases disease 0.328 (D. Slamon et al., 2011) 
Annual rate of death from other disease Age specific (WHO, 2014b) 
AC-T: doxorubicin and cyclophosphamide followed by docetaxel. 
AC-TH: doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab. 
DFS: disease free survival. 
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In BCIRG 006 trial at a median follow-up of 65 months, DFS rate at 5 years was 75% among the patients 
receiving AC-T and this rate was 84% among those receiving AC-T plus trastuzumab. Based on a same trial, the 
hazard ratio for recurrence in the control group, compared with the observation group, was 0.64 (95% confidence 
interval, 0.53–0.78; p<0.0001) (D. Slamon et al., 2011).Breast cancer recurrence rate in the first group was taken 
from the control group of the BCIRG 006 trial. The proportion of recurrences that are local versus metastases 
diseases was derived from the HERA trial (Piccart-Gebhart et al., 2005). The probability of death from 
metastases in both strategies obtained from the control group of trastuzumab’s RCT (D. J. Slamon et al., 2001). 
The proportion of patients experiencing congestive heart failure in both groups was obtained from the BCIRG 
006 trial. Age specific background mortality rates for 50 to 70 year old women were derived from the Iranian life 
table (WHO, 2014b). 
2.4 Quality of Life 
We adjusted survival with quality of life using utility weights for years that every patient spent in each state. 
These weights were derived from the existent literature (see Table 2).  
 
Table 2. Utility value of different health states 
Health state Base-case utility weight Reference 
Treatment With AC-T 0.94 (C. R. Earle CC, Baker CS, Bell CM, Stone PW, Sandberg 
EA, Neumann PJ., 2000) 
Treatment With AC-TH 0.94 (C. R. Earle CC, Baker CS, Bell CM, Stone PW, Sandberg 
EA, Neumann PJ.) 
Disease Free Survival 0.98 (C. R. Earle CC, Baker CS, Bell CM, Stone PW, Sandberg 
EA, Neumann PJ.) 
Congestive heart Failure 0.64 (Lewis et al., 2001) 
Loco- Regional Recurrence 0.615 (Lidgren, Wilking, Jönsson, & Rehnberg, 2007) 
Distant Recurrence 0.615 (Lloyd, Nafees, Narewska, Dewilde, & Watkins, 2006) 
 
2.5 Costs 
Direct medical costs were measured from the perspective of the Iranian health care system only. Direct 
non-medical and indirect costs such as transportation cost, out-of-pocket payments, time spend for seeking care 
and loss of productivity were not measured in our study. To calculate the dosage of drugs, treatment expense for 
an assumed average 70kg woman was used (Larijani, 2005). Costs are expressed in US dollars. Costs were 
inflated to 2010 prices using the Consumer price index (CPI) for the country. Sources of cost inputs are 
presented in Table 3. 
 
Table 3. Cost parameters 
Cost description Base case estimate 
(USD) 
Reference 
AC-T treatment overall cost 3294 (Haghighat, 2013) 
Trastuzumab drug cost 48850 (ICRN, 2011) 
Trastzumab administration cost 425 Local charge 
Annual disease free Follow-up costs 
(mammography, medical visits, for 3 years) 
47 Calculated based on Guideline (NICE, 2002)  
Loco-regional overall cost 4138 (Haghighat, 2013) 
Metastases diseases annual cost 7865 (Davari et al., 2013) 
Congestive heart failure cost 675 Calculated based on Guideline (NICE, 2010) 
AC-T: doxorubicin and cyclophosphamide followed by docetaxel. 
AC-TH: doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab. 
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Costs of local recurrences including costs of surgery, chemotherapy, radiotherapy, hormonal therapy and 
hospitalization were adopted from an earlier study in Iran (Haghighat, 2013). The costs of metastatic disease 
including hospitalization, surgery, chemotherapy, radiotherapy, hormonal therapy, palliative and terminal care, 
were derived from a cost study in Iran (Davari et al., 2013). We assumed that adjuvant hormone therapy with an 
aromatase inhibitor was received for 5 years by 70% of the patients in both groups (Haghighat, 2013). The cost 
of trastuzumab therapy was not considered in local and metastatic phases. Other local costs of Trastuzumab 
therapy in the adjuvant setting including HER2/neu screening, drug administration, supportive medications, and 
patient management, were obtained through a general hospital (Imam Khomeini hospital) in Tehran city. Costs of 
managing congestive heart failure were calculated based on international guideline (NICE, 2010). 
The costs of follow-up examinations for disease-free patients were calculated according to international 
guidelines and based on local charge (NICE, 2002). 
2.6 Sensitivity Analysis 
To assess the robustness of the study results, one-way sensitivity analyses were performed. We changed input 
parameters between the upper and lower frontier according to experts’ advice, and explored the results. 
3. Results 
The model results was expressed in terms of life years saved (LYs), quality-adjusted life years (QALYs) and 
incremental cost-effectiveness ratios (ICER). The results of the analysis are summarized in Table 4. 
 
Table 4. Base case results 
Parameters AC-T AC-TH Difference ICER (USD) 
20-year treatment and fallow-up costs (USD) 12388 56984 44596 --- 
Life years gained (LYGs)  11.81 12.63 0.82 54223 
Quality-adjusted life years gained (QALYs)  11.11 11.98 0.87 51302 
 
In the base case analysis (i.e. over 20-year time horizon) the QALYs gained with AC-T regimen (strategy 1) and 
with 52 weeks adjuant trastuzumab treatment for HER2-positive patients (strategy 2) were 11.11 and 11.98, 
respectively. Therefore, the new intervention produced an extra 0.87 QALYs. The total costs for AC-T adjuant 
and AC-T adjuant treatments were 12,388 USD and 56,984 USD, respectively. The base case analysis indicated 
that treatment with a 12-month adjuvant trastuzumab regimen generated an ICER of 51,302 USD per QALY.  
3.1 Sensitivity Analysis 
One-way sensitivity analyses were undertaken to assess robustness of the study results. Result of this analysis 
presented in Table 5. 
 
Table 5. Results of sensitivity analyses in incremental cost-effectiveness ratios (ICER) (USD) 
Variable  Lower  Upper 
Cost of trestuzumab(-30%/+30%) 34296 68307 
Cost of treating metastases(-30%/+30%) 50807 51795 
Discount rate (0%/ 6%) 37775 67661 
Cost of congestive heart failure(-30%/+30%) 51159 51403 
Utility Weight of DFS (0.75/1) 50174 69169 
Utility Weight of metastases (0.45/0.75)  49588 52794 
Hazard ratio for DFS (0.37/.64) 43887 51302 
The ICER for the base case = 51302 USD/QALY.   
 
Sensitivity analyses of variables in the model showed that model is sensitive to changes in the cost of 
trastuzumab, discount rate for outcomes and hazard ratio in AC-TH group. In order to assess model validation, 
the results of the model for two treatment strategies were compared with overall survival at 5 years in BCRG006 
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trial. Overall survival at 5 years in BCRG006 trial reported 92% and 87% in AC-T and AC-TH group. In our 
Markov model, overall survival in same period is 93% and 85%. 
4. Discussion 
In developed countries, 1-year adjuvant trastuzumab treatment is cost-effective in early breast cancer treatment, 
particularly in a long-term perspective (Garrison et al., 2007; Hedden et al., 2012; Liberato et al., 2007). This 
costly adjuvant treatment in early breast cancer reduces risk of metastasis disease and improves overall survival 
(D. Slamon et al., 2011). In developing countries, however, there is some uncertainty about the 
cost–effectiveness of this regimen (Buendía et al., 2013). 
In base case analysis, our model yielded an ICER with 51302 USD per QALY after 20 years for the BCIRG-006 
trial. High cost–effectiveness ratio yielded in our study is comparable with similar studies (Garrison et al., 2007; 
Hedden et al., 2012; Liberato et al., 2007) evaluating cost-effectiveness of trastuzumab conducted in developed 
countries. For example, a study in Italy by Liberato and colleagues (Liberato et al., 2007) with 5-year benefit 
duration and with 15-year time horizon, cost per QALY estimated 22,385 USD. They concluded that adjuvant 
trastuzumab treatment in early breast cancer is cost-effective. This estimate is lower than our ICER estimate. The 
difference between this finding and our result can be explained by the shorter time horizon and lower relative 
risk applied in trastuzumab group in the study by Liberato et al.(2007). Moreover, according to HERA trial, 
relative risk of any relapse was 0.4 in the Liberato et al. study. Additionally, in the Italian study, high cost of 
trstuzumab was estimated in metastatic disease treatment.  
In a study by Garrison et al. (2007), with a 20-year time horizon, the incremental cost per QALY was calculated 
34,201 USD. Some of the assumptions used in the Garrison et al. study is similar to our study, such as time 
horizon (20 years), length of benefit duration (5 years) and discount rate (3%). However, their study is 
constructed upon the joined analysis of the NCCTG N9831 and NSABP trials. Therefore, transitional probability 
for disease free survival in their study differs from the input we used in our analysis. 
In a study by Hedden and colleagues (Hedden et al., 2012), with 5-year benefit duration and 5% discount rate 
and 28-year time horizon, the cost effectiveness of trastuzumab was calculated 13,095 USD per QALY.. Lower 
cost-effectiveness ratio in this study, comparing with other similar studies, is due to high survival rate of patients 
and cost of trastuzumab for relapse treatment (Hedden et al., 2012). In Iran, less than 5% of patients, particularly 
in relapse state, receive trastuzumab (Davari et al., 2013). Majority of patients receive a cheaper alternative 
treatment regimen, such as standard chemotherapy plus taxane. Therefore, we did not calculate cost of 
trastuzumab in the metastases state. We believe that the main reason for the high cost-effectiveness ratio in our 
analysis, compared to the similar studies in other settings, is lower treatment costs for metastases state. Some 
part of the lower costs, compared with developed countries settings, can be explained by the subsidized health 
care system and also lower cost of services in Iran. For example, in Dedes et al.(Dedes et al., 2007) study, costs 
of treating metastatic estimated 41,412 EUR, while these costs was estimated less than 20% of this figure in Iran. 
Majority of economic evaluations studies in developed countries have predicted that adding trastuzumab to 
chemotherapy is cost-effective relative to other breast-cancer therapies. Trastuzumab remained a cost-effective 
treatment strategy in developed countries with a high willingness-to-pay threshold. For example, the National 
Institute for Health and Clinical Excellence (NICE) estimated that adjuvant trastuzumab treatment in the United 
Kingdom has an incremental cost per QALY gained of £18,000, which is less than the general £30,000 threshold 
(NICE, 2006). Methodologies and the geographic contexts conclusions may differ between developing countries 
reports as a result of different assumptions. In a study in Colombia, based on therapy regimens and results from 
the 4 year fallow up of the NCCTG N9831 and NSABP trials, Buendia and colleagues estimates that adjuvant 
trastuzumab has an incremental cost per QALY gained of USD71491. Buendia and colleagues (2013) used a 
20-year horizon in the base case, 5% discounted rate, and also assumed no additional trastuzumab benefit after 5 
years. The QALY differential estimate from our study is similar to Buendia et al’s study. Buendia et al’s 
projected differential in discounted QALYs was 0.80 versus 0.87 in the present study. Our base case estimate for 
the ICER is USD 51302, which is lower than the estimate calculated in the Colombian study, due in part to the 
different cost estimation, different discount rate and different hazard ratio. Buendia and colleagues concluded 
that trasutuzumab is not a cost-effective therapy for HER2-positive, early breast cancer-adjuvant. 
Willingness-to-pay and acceptable threshold in developing countries such as Iran and Colombia has not been 
determined yet. Therefore, we used the WHO cost-effectiveness threshold (i.e., less than 3 times GDP per capita 
of the country) for relative cost-effectiveness in our study (WHO, 2014a). This threshold in Iran would be lower 
than developed countries. According to experts’ opinion this threshold for Iran estimated to be between 10,000 
to15,000 USD (WHO, 2014a). 
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Since 2007, the Iranian Ministry of Health and Medical Education provides some financial supports for patients 
but trasutuzumab is not covered with current insurances schemes. The high price of this drug can impose 
catastrophic expenditure to the patients and their households.  
One of the strengths of our study was that our clinical data were derived from 5-year analyses of BCIRG006 
clinical trials, while most of the cost-effectiveness analyses done on trastuzumab, are based on a one-year HERA 
trials. Our analysis, nevertheless, has few limitations need to be acknowledged. First, we estimated only the 
direct medical costs from the health care system perspective and direct non-medical and indirect costs such as 
transportation cost, out-of-pocket payments, time spend for seeking care and loss of productivity were not 
measured in our study. Indirect costs and productivity gains are possibly substantial and adding these costs to the 
model would have increased lifetime costs. Second, some of the cost components such as the costs of managing 
congestive heart failure and cost of follow up for disease-free patients, were estimated based on international 
guidelines and may not reflect the real costs. Finally, due to the lack of utility weights for the breast cancer 
patients in Iran, utility weights were obtained from other settings than Iran. Geographical and cultural difference 
between countries may affect utility weights. 
5. Conclusion 
Using WHO cost-effectiveness threshold base on GDP per capita, 12 months trastuzumab adjuvant 
chemotherapy in early breast cancer is not a cost-effective therapy for the patients with HER2-positive in Iran.  
5.1 Ethical Issues 
This study was approved by the Ethics Committee of Iran University of Medical Sciences. 
Acknowledgment 
This study was part of PhD. dissertation supported by Iran University of Medical Sciences (Grant NO: 
IUMS/SHMIS-789-2012). 
Competing Interests Statement 
All authors declare that they have no significant competing financial, professional, or personal interests that 
might have influenced the performance or presentation of the work described in this manuscript. 
References 
Buendía, J. A., Vallejos, C., & Pichón-Rivière, A. (2013). An economic evaluation of trastuzumab as adjuvant 
treatment of early HER2-positive breast cancer patients in Colombia. Biomédica: Revista del Instituto 
Nacional de Salud, 33(3), 832. http://dx.doi.org/10.7705/biomedica.v33i3.832 
Davari, M., Yazdanpanah, F., Aslani, A., Hosseini, M., Nazari, A. R., & Mokarian, F. (2013). Direct Medical 
Costs of Breast Cancer in Iran; Analyzing Patients Level Data from a Cancer Specific Hospital in Isfahan, 
Iran. Health information management, 31, 46. 
Dedes, K. J., Szucs, T. D., Imesch, P., Fedier, A., Fehr, M. K., & Fink, D. (2007). Cost-effectiveness of 
trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and 
FinHer trial. Annals of oncology, 18(9), 1493-1499. http://dx.doi.org/10.1093/annonc/mdm185 
Earle, C. C., Chapman, R. H., Baker, C. S., Bell, C. M., Stone, P. W., Sandberg, E. A., & Neumann, P. J. (2000). 
Systematic overview of cost-utility assessments in oncology. Clin Oncol, 18(18), 3302-3317. 
http://dx.doi.org/10.1371/journal.pone.0029775 
EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 
15-year survival: An overview of the randomised trials. Lancet, 365, 1687-1717. 
http://dx.doi.org/10.1136/ebm.10.6.169 
Etemad, K., Gooya, M., Ramezani, R., & Modirian, M. (2008-9). National Cancer Registry Report. Tehran, Iran: 
Ministry of Health, Deputy for Health Directory, CDC Cancer Office. 
Fenton, E. (2010). Making fair funding decisions for high cost cancer care: the case of Herceptin in New Zealand. 
Public Health Ethics, 3(2), 137-146. http://dx.doi.org/ 10.1093/phe/phq011 
Fleck, L. M. (2006). The costs of caring: Who pays? Who profits? Who panders? Hastings Center Report, 36(3), 
13-17. http://dx.doi.org/10.1353/hcr.2006.0040 
Garrison, L. P., Lubeck, D., Lalla, D., Paton, V., Dueck, A., & Perez, E. A. (2007). Cost-effectiveness analysis of 
trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer, 110(3), 489-498. 
http://dx.doi.org/10.1002/ cncr.22806. 
www.ccsenet.org/gjhs Global Journal of Health Science Vol. 7, No. 1; 2015 
105 
 
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., ... Jackisch, C. (2011). 
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early 
breast cancer: A 4-year follow-up of a randomised controlled trial. The lancet oncology, 12(3), 236-244. 
http://dx.doi.org/10.1016/S1470-2045(11)70033-X  
Haghighat, S. (2013). Cost-effectiveness of Mammography Screening for Breast Cancer in Iranian female. 
Shahid Beheshti University of Medical Sciences, Tehran. 
Hall, P. S., Hulme, C., McCabe, C., Oluboyede, Y., Round, J., & Cameron, D. A. (2011). Updated 
Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. Pharmacoeconomics, 29(5), 415-432. 
http://dx.doi.org/10.2165/11588340-000000000-00000 
Hedden, L., O'Reilly, S., Lohrisch, C., Chia, S., Speers, C., Kovacic, L., ... Peacock, S. (2012). Assessing the 
real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. The oncologist, 
17(2), 164-171. http://dx.doi.org/10.1634/theoncologist.2011-0379 
Hudis, C. A. (2007). Trastuzumab-mechanism of action and use in clinical practice. New England Journal of 
Medicine, 357(1), 39-51. http://dx.doi.org/10.1056/NEJMra043186 
ICRN. (2011). Trastuzumab Guideline. Tehran, Iran: Nashre Daneshgahi Publication Enterprise. 
Kurian, A. W., Thompson, R. N., Gaw, A. F., Arai, S., Ortiz, R., & Garber, A. M. (2007). A cost-effectiveness 
analysis of adjuvant trastuzumab regimens in early HER2/neu–positive breast cancer. Journal of Clinical 
Oncology, 25(6), 634-641. http://dx.doi.org/10.1200/ JCO.2006.06.3081 
Larijani, B., Hossein-Nezhad, A., Mojtahedi, A., Pajouhi, M., Bastanhagh, M. H., Soltani, A., … Dashti, R. 
(2005). Normative data of bone Mineral Density in healthy population of Tehran, Iran: a cross sectional 
study. BMC Musculoskelet Disord, 6, 38.  
Lewis, E. F., Johnson, P. A., Johnson, W., Collins, C., Griffin, L., & Stevenson, L. W. (2001). Preferences for 
quality of life or survival expressed by patients with heart failure. The Journal of Heart and Lung 
Transplantation, 20(9), 1016-1024. http://dx.doi.org/10.1353/hcr.2006.0040 
Leyland-Jones, B. (2002). Trastuzumab: Hopes and realities. The lancet oncology, 3(3), 137-144. 
http://dx.doi.org/10.1016/S1470-2045(02)00676-9  
Liberato, N. L., Marchetti, M., & Barosi, G. (2007). Cost effectiveness of adjuvant trastuzumab in human 
epidermal growth factor receptor 2–positive breast cancer. Journal of Clinical Oncology, 25(6), 625-633. 
http://dx.doi.org/10.1200/JCO.2006.06.4220 
Lidgren, M., Wilking, N., Jönsson, B., & Rehnberg, C. (2007). Health related quality of life in different states of 
breast cancer. Quality of life research, 16(6), 1073-1081. http://dx.doi.org/10.1007/s11136-007-9202-8 
Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., & Watkins, J. (2006). Health state utilities for metastatic breast 
cancer. British journal of cancer, 95(6), 683-690.  
Millar, J. A., & Millward, M. J. (2007). Cost effectiveness of Trastuzumab in the adjuvant treatment of early 
breast cancer. Pharmacoeconomics, 25(5), 429-442.  
Mousavi, S. M., Gouya, M. M., Ramazani, R., Davanlou, M., Hajsadeghi, N., & Seddighi, Z. (2009). Cancer 
incidence and mortality in Iran. Ann Oncol., 20, 556-563. http://dx.doi.org/10.1093/annonc/mdn642 
Neyt, M., Huybrechts, M., Hulstaert, F., Vrijens, F., & Ramaekers, D. (2008). Trastuzumab in early stage breast 
cancer: A cost-effectiveness analysis for Belgium. Health Policy, 87(2), 146-159. 
http://dx.doi.org/10.1016/j.healthpol.2007.11.003 
NICE. (2002). Guidance on cancer services: Improving outcomes in breast cancer manual update. London: 
National Institute for Clinical Excellence. 
NICE. (2006). Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer: NICE 
technology appraisal guidance 107.   
NICE. (2010). Congestive heart failure.  
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., ... Jackisch, C. 
(2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of 
Medicine, 353(16), 1659-1672. http://dx.doi.org/10.1056/NEJMoa052306 
Rivkin, S. E., Green S. J., Lew, D., Costanzi, J. J., Athens, J. W., Osborne, C. K., … Martino, S. (2003). 
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and 
www.ccsenet.org/gjhs Global Journal of Health Science Vol. 7, No. 1; 2015 
106 
 
prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast 
carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer, 
97(1), 21-29.  
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer Jr, C. E., Davidson, N. E., ... Kaufman, P. A. (2005). 
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal 
of Medicine, 353(16), 1673-1684. http://dx.doi.org/10.1056/ 
Sadjadi, A., Nouraie, M., Mohagheghi, M. A., Mousavi-Jarrahi, A., Malekezadeh, R., & Parkin, D. M. (2005). 
Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev., 6, 359-363.  
Skedgel, C., Rayson, D., & Younis, T. (2009). The Cost-Utility of Sequential Adjuvant Trastuzumab in Women 
with Her2/Neu‐Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. 
Value in Health, 12(5), 641-648. http://dx.doi.org/10.1111/j.1524-4733.2009.00511 
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., ... Ullrich, A. (1989). Studies of 
the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712. 
http://dx.doi.org/10.1126/science.2470152 
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... Pegram, M. (2001). Use of 
chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses 
HER2. New England Journal of Medicine, 344(11), 783-792. 
http://dx.doi.org/10.1056/NEJM200103153441101 
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., ... Pawlicki, M. (2011). Adjuvant 
trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, 365(14), 1273-1283. 
http://dx.doi.org/10.1056/NEJMoa0910383.  
WHO. (2014a). Cost-effectiveness and strategic planning . http://www.who.int/choice/costs/CER_levels/en/ 
WHO. (2014b). The WHO country health profile of Iran (Islamic Republic of). Retrieved from 
http://www.who.int/countries/irn /en/ 
 
Copyrights 
Copyright for this article is retained by the author(s), with first publication rights granted to the journal. 
This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution 
license (http://creativecommons.org/licenses/by/3.0/). 
 
